Technical Analysis for BGNE - BeiGene, Ltd.
|Grade||Last Price||% Change||Price Change|
BGNE closed up 0.14 percent on Tuesday, May 22, 2018, on 54 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
|See historical BGNE trend table...|
|Date||Alert Name||Type||% Chg|
|May 22||Calm After Storm||Range Contraction||0.00%|
|May 22||NR7||Range Contraction||0.00%|
|May 22||Inside Day||Range Contraction||0.00%|
|May 22||Overbought Stochastic||Strength||0.00%|
|May 21||Calm After Storm||Range Contraction||0.14%|
|May 21||New 52 Week High||Strength||0.14%|
|May 21||Stochastic Reached Overbought||Strength||0.14%|
|May 21||Upper Bollinger Band Walk||Strength||0.14%|
|May 21||Multiple of Ten Bearish||Other||0.14%|
|May 21||Multiple of Ten Bullish||Other||0.14%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more BGNE news...
|52 Week High||202.88|
|52 Week Low||36.51|
|200-Day Moving Average||117.3937|
|50-Day Moving Average||171.6738|
|20-Day Moving Average||180.2745|
|10-Day Moving Average||185.047|
|Average True Range||8.3616|
|Chandelier Exit (Long, 3 ATRs )||177.7952|
|Chandelier Exit (Short, 3 ATRs )||185.6048|
|Upper Bollinger Band||197.2308|
|Lower Bollinger Band||163.3182|
|Percent B (%b)||0.89|
|MACD Signal Line||5.1886|
|Market Cap||7.71 Billion|
|Num Shares||39.8 Million|
|Price-to-Earnings (P/E) Ratio||-38.93|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||201.46|
|Resistance 3 (R3)||201.41||198.71||200.13|
|Resistance 2 (R2)||198.71||196.67||198.73||199.69|
|Resistance 1 (R1)||196.09||195.42||197.40||196.14||199.24|
|Support 1 (S1)||190.77||191.35||192.08||190.82||187.72|
|Support 2 (S2)||188.07||190.10||188.09||187.27|
|Support 3 (S3)||185.45||188.07||186.83|
|Support 4 (S4)||185.50|